Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SH) Latest Company News

Oct 28, 2026, 10:08 UTC
China's National Medical Products Administration approved clinical trials for BC923 injection and BC008-1A injection, developed by subsidiaries of Buchang Pharmaceutical.
Source:
- finance.sina.cn
Oct 9, 2026, 08:43 UTC
China's National Medical Products Administration approved and issued a Drug Registration Certificate for Shandong Buchang Pharmaceuticals' atomoxetine hydrochloride oral solution.
Source:
- finance.sina.cn
Sep 29, 2026, 10:57 UTC
Luzhou Buchang, a controlled subsidiary of Buchang Pharmaceutical, plans to invest 40 million yuan of its own cash to establish Hangzhou Buchang New Drug R&D Co., Ltd., wholly owned at 100%.
Source:
- finance.sina.cn
Sep 27, 2026, 07:38 UTC
Buchang Pharmaceuticals plans to increase capital by a total of 4 million yuan in cash at 1 yuan per share together with other shareholders of its controlling subsidiary Jinan Buchang Chicheng Trading Co., Ltd. in proportion to their existing shareholdings, of which Buchang Pharmaceuticals contributes 3.64 million yuan; after the increase, the registered capital of Buchang Chicheng Trading will rise from 1 million yuan to 5 million yuan.
Source:
- finance.sina.cn
Sep 21, 2026, 09:01 UTC
Shanghai Hepu Medical Technology, a controlled subsidiary of Buchang Pharmaceutical, obtained a renewed Medical Device Business License from the Shanghai Fengxian District Market Supervision Administration, with the change mainly involving a warehouse address adjustment and the license valid until September 24, 2029.
Source:
- finance.sina.cn
Sep 15, 2026, 08:00 UTC
Shandong Buchang Pharmaceuticals' controlling subsidiary Beijing Hepu Jingyuan Medical Technology obtained a renewed Medical Device Business License from the Beijing Huairou District Market Supervision Administration, with changes limited to domicile, business premises and warehouse addresses.
Source:
- finance.sina.cn
Aug 28, 2026, 07:35 UTC
Stepun Pharmaceutical's wholly-owned subsidiary Baoding Tianhao Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for terbinafine hydrochloride spray, a Class 4 chemical OTC drug for treating fungal skin infections.
Source:
- finance.sina.cn
Aug 27, 2026, 10:17 UTC
Step Pharmaceutical announced its first-half 2026 results, with revenue of 5.003 billion yuan, down 11.67% year-on-year, and net profit of 503 million yuan, down 19.93% year-on-year.
Source:
- finance.sina.cn
Aug 17, 2026, 11:50 UTC
Shandong Buchang Pharmaceutical Co., Ltd. and Professor Zhao Buchang, as the first completing unit and first completer, were awarded the First Prize of the 2025 Shandong Province Science and Technology Progress Award for their project on digital-intelligent technology for the whole traditional Chinese medicine industry chain.
Source:
- wap.eastmoney.com
Aug 17, 2026, 09:16 UTC
Step Pharmaceutical's controlled subsidiary Beijing Boyuan Runbu Pharmaceutical R&D Co., Ltd. received acceptance from China's National Medical Products Administration for its clinical trial application for the drug BC923 injection, a Class 1 chemical drug for hypertension.
Source:
- finance.sina.cn

603858.SH

China's National Medical Products Administration approved clinical trials for BC923 injection and BC008-1A injection, developed by subsidiaries of Buchang Pharmaceutical.

China's National Medical Products Administration approved and issued a Drug Registration Certificate for Shandong Buchang Pharmaceuticals' atomoxetine hydrochloride oral solution.

Luzhou Buchang, a controlled subsidiary of Buchang Pharmaceutical, plans to invest 40 million yuan of its own cash to establish Hangzhou Buchang New Drug R&D Co., Ltd., wholly owned at 100%.

Shandong Buchang Pharmaceuticals' controlling subsidiary Beijing Hepu Jingyuan Medical Technology obtained a renewed Medical Device Business License from the Beijing Huairou District Market Supervision Administration, with changes limited to domicile, business premises and warehouse addresses.

Stepun Pharmaceutical's wholly-owned subsidiary Baoding Tianhao Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for terbinafine hydrochloride spray, a Class 4 chemical OTC drug for treating fungal skin infections.

Step Pharmaceutical announced its first-half 2026 results, with revenue of 5.003 billion yuan, down 11.67% year-on-year, and net profit of 503 million yuan, down 19.93% year-on-year.

Step Pharmaceutical's controlled subsidiary Beijing Boyuan Runbu Pharmaceutical R&D Co., Ltd. received acceptance from China's National Medical Products Administration for its clinical trial application for the drug BC923 injection, a Class 1 chemical drug for hypertension.